Merck's Global Creative Review Covers 3 Drugs

Total media spending estimated at $50 million

Be among trailblazing marketing pros at Brandweek this September 23–26 in Phoenix, Arizona. Experience incredible networking, insightful sessions and a boost of inspiration at ADWEEK’s ultimate brand event. Register by May 13 to save 35%.

The Merck & Co. consumer brands in play in the company’s global creative review are Dr. Scholl’s, Miralax and an incontinence drug for women that’s shifting from prescription to over-the-counter sales.
The company’s initial request for proposals doesn’t name the incontinence drug. Collective media spending on the business in review is estimated at $50 million.
Merck is seeking a second global agency to work along side Euro RSCG on its non-prescription consumer brands. The Miralax and female incontinence drug assignments are global and the Dr.

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in